XV 459
| Code | Size | Price |
|---|
| TAR-T35192-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
XV 459 is a biochemical.
CAS:
170902-52-0
Formula:
C20H27N5O6
Molecular Weight:
433.465
Purity:
0.98
SMILES:
CCCCOC(=O)N[C@@H](CNC(=O)C[C@H]1CC(=NO1)c1ccc(cc1)C(N)=N)C(O)=O
References
Pieniaszek HJ Jr, Davidson AF, Walton HL, Pinto DJ, Olson RE, Reilly TM, Barrett YC. A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma. J Pharm Biomed Anal. 2003 Jan 1;30(5):1441-9. PubMed PMID: 12467915.
Fossler MJ, Ebling WF, Ma S, Kornhauser D, Mondick J, Barrett JS, Garner D, Quon CY, Pieniaszek HJ Jr. Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers. J Clin Pharmacol. 2002 Dec;42(12):1326-34. PubMed PMID: 12463727.
Mousa SA, Ahmad S. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. Am J Hematol. 2007 Apr;82(4):276-82. PubMed PMID: 17039513.
Pieniaszek HJ Jr, Sy SK, Ebling W, Fossler MJ, Cain VA, Mondick JT, Ma S, Kornhauser DM. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. J Clin Pharmacol. 2002 Jul;42(7):738-53. PubMed PMID: 12092741.